GlassScriptPhysician profile
Derek L Reeder
NPI 1457751091
$4,355.68
in general payments reported to CMS, 2019-2025
33 companies · $1,164 in 2025
The $1,164 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $203 · 2022: $754 · 2023: $1,410 · 2024: $824 · 2025: $1,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,399.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,807.12 | 2021-2025 | |
| Pfizer INC. | $444.75 | 2021-2025 | |
| Lilly USA, LLC | $266.53 | 2021-2025 | Mounjaro, Emgality, Zepbound |
| Novartis Pharmaceuticals Corporation | $261.42 | 2023-2025 | |
| Novo Nordisk INC | $194.27 | 2021-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $171.61 | 2022-2025 | |
| Amgen INC. | $168.49 | 2022-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $166.11 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $90.93 | 2023-2025 | Farxiga, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $79.48 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $78.07 | 2022-2023 | Spravato |
| Biohaven Pharmaceutical Holding Company LTD. | $67.93 | 2022 | |
| Phathom Pharmaceuticals, INC. | $53.95 | 2025 | Voquezna |
| Glaxosmithkline, LLC. | $53.41 | 2023-2025 | Shingrix, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $49.66 | 2024 | Rexulti |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $47.36 | 2022-2023 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $35.76 | 2025 | Fanapt, Hetlioz |
| Insulet Corporation | $29.67 | 2024-2025 | Omnipod |
| Dexcom, INC. | $25.36 | 2021 | |
| Ironwood Pharmaceuticals, INC | $23.66 | 2024 | |
| Siemens Medical Solutions USA, INC. | $23.20 | 2024 | Dca Systems Hemoglobin A1c Reagent Kit |
| Hologic Sales and Service, LLC | $22.68 | 2023 | Aptima |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.11 | 2023 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $21.42 | 2021 | |
| Abbott Laboratories | $20.85 | 2023 | Freestyle Libre 3 |
| Ultragenyx Pharmaceutical INC. | $20.12 | 2023 | |
| Amarin Pharma, INC. | $20.00 | 2021 | |
| Philips North America LLC | $19.54 | 2024 | (Ck7) Extended Holter |
| Axsome Therapeutics, INC. | $16.23 | 2025 | Symbravo |
| Angiodynamics, INC. | $15.06 | 2023 | Solero |
| Merck Sharp & Dohme LLC | $13.84 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Idorsia Pharmaceuticals US INC | $13.64 | 2023 | Quviviq |
| Vbi Vaccine (Delaware) INC. | $11.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Reeder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.